Objective: To report the tolerance of indinavir combined with ritonavir (IDV/r 800/100mg) twice daily (bid) in sub-Saharan African HIV-infected adults.
Introduction
The benefits of pharmacokinetically enhanced protease inhibitor (PI) regimens using ritonavir (RTV) as a booster have long been demonstrated [1, 2] . RTV boosting reduces the number of drug intake -thus also reducing the treatment cost -, and diminishes the constraints of food and water requirements, especially for Indinavir (IDV) [3] . RTV-boosted PI (PI/r) regimens are currently rarely employed in sub-Saharan Africa, because RTV soft capsules need to be stored below 25°C. Although World Health Organisation (WHO) experts recognize that PI/r regimens represent valuable alternatives to non nuclesoside reverse transcriptase inhibitors (NNRTI)-based regimens [4, 5] , no experience of their use has been reported in sub-Saharan Africa so far.
We report here the 6 month-efficacy and tolerance of a highly active antiretroviral treatment (HAART) based on an indinavir/ritonavir (IDV/r) 800/100 mg twice daily (bid) regimen in a cohort of HIV-1 infected patients in Abidjan, the economic capital city of Côte d'Ivoire, West Africa.
Patients and Methods
In December 2002, a randomised trial (Trivacan ANRS 1269) of structured treatment interruptions (STI) was launched in Abidjan [6] . The trial protocol was approved by the ethics committee of the Ministry of Health of Côte d'Ivoire and the institutional review board of the French Agency of Research on AIDS (ANRS, Paris, France). Inclusion criteria in the trial have been previously described [7] . Between inclusion and randomisation in the STI arms, patients received at least 6 months of continuous HAART. We describe here the 6-month outcomes of treatment-naïve patients who started an IDV/r-based regimen at inclusion in the pre-randomisation phase of the trial.
At inclusion, and every month thereafter, patients received 35 days of treatment, i.e. 70 tablets of Duovir ® (ZDV 300 mg and 3TC 150, Cipla LTD, Mumbai, India), 140 tablets of Crixivan ® (IDV 400 mg, Merk Sharp and Dohme, Haarlem, The Netherlands) and 70 soft capsules of Norvir ® (RTV 100 mg, Abbott, Zwolle, The Netherlands). At inclusion, patients were recommended to ingest a minimum of two litters of water per day. They were asked to return to their study centre at day seven, at month-1 (M1) and every month thereafter. During these monthly visits, questionnaires were administered to record adherence to treatment during the previous four days. Patients had free access to the study clinics whenever they had a medical problem. Symptoms were managed following standardized algorithms of treatment [8] . Applied Biosystems, limit of detection at 300 copies/mL) [9] , serum liver enzymes and creatininemia were measured. Additional samples were collected at M1, M3 and M6 for plasma and serum depository (storage in a -80°C deep-freezer). Patients were asked not to take their morning drugs before month-1, month-3 and month-6 blood sample collections.
Blood collections were thus performed early in the morning, in patients whose last drug intake was on the previous evening.
In August 2005, all deep-freezed stored samples were sent to France for IDV and ZDV plasma concentration measurements by means of high performance liquid chromatography coupled with UV-detection (respective LOQ 5 and 10 ng/mL with previously described methods) [10, 11] . Patients with a ZDV plasma concentration above 10 ng/mL were suspected to have taken their treatment within the preceding eight hours. Consequently, their IDV plasma concentrations were considered as non-minimal concentrations (non-C min). For all other patients, the IDV concentration was classified as minimal concentration (C min ). The value of 10 ng/mL eight hours after the last drug intake was chosen according to the pharmacokinetic characteristics of ZDV in HIV-infected patients with normal renal function [12] . (reduction to IDV/r 400/100mg bid: n=10; switch for efavirenz: n=10; reduction to 400/100mg bid followed by switch for efavirenz: n=1) and one patient with a modification for severe anaemia (zidovudine replaced by stavudine). All digestive intolerance events were severe vomiting, including four with admission to the day care hospital for intravenous treatment, two with associated sub-icterus, and one with grade 3 elevation of transaminases.
There was no other grade 3 or grade 4 hepatitis.
No renal insufficiency of any grade and no symptom evocative of uro-nephrological lithiasis were documented. The median creatinine clearance was estimated at 114 ml/min (IQR 103;132) at baseline and 100 ml/min (80;119) at M6 (median difference between baseline and M6: -12 ml/min , IQR -32;+ 0.0). Table 2 shows the number of patients who: (1) were still receiving IDV/r 800/100 mg bid, (2) had been reduced to IDV/r 400/100mg bid, and (3) had been switched for a non IDVcontaining regimen at M1, M3 and M6. Figure 1 describes IDV plasma C min and non-C min in patients still receiving IDV/r 800/100 mg bid.
Discussion
Within our cohort study of sub-Saharan African adults starting a IDV/r 800/100 mg bid containing regimen, the percentage of patients with an undetectable viral load at month-6 and the mean gain in CD4 after 6 months of follow-up were in the lower bracket of those previously described in industrialized countries [13] [14] [15] . Meanwhile: (i) the percentage of patients with severe digestive intolerance leading to IDV/r dosage reduction or to IDV/r replacement by another drug reached 30%; (ii) the mean IDV concentration in patients still on the 800/100 mg bid dosage decreased within time, suggesting that a significant proportion of patients who were not asked by the medical team to reduce the IDV/r dosage to 400/100 mg bid probably decided by themselves to interrupt the treatment; (iii) IDV C min were in the upper bracket of those previously reported in patients receiving the 800/100 mg bid regimen [3, 14, 16, 17] ; (iv) In spite of these high concentrations, there was no episode of uronephrological side-effects.
To our knowledge, this is the first time that an experience with IDV/r is reported in subSaharan Africa. In industrialized countries, urinary stones have been reported to occur in 18% to 33% of patients on IDV/r 800/100 mg bid [13, 14] . IDV nephrological toxicity has been associated with a high urinary pH, a low diuresis, a high concentration of the parent drug or its metabolites in urine, an increasing area under the curve, an IDV C min above 500 ng/ml, a low lean body mass, warm weather environments, and the concomitant use of aciclovir [16, 18, [19] [20] [21] [22] . In tropical areas with high temperatures and high levels of humidity, the IDV concentration in urine would have been expected to be higher, thus resulting in higher uronephrological toxicity [22, 23] . Furthermore, the urinary pH of HIV-infected adults living in West Africa has been reported to be higher than that of European adults, and this should also result in a higher frequency of IDV related nephrolithiasis in Africa [24] . Finally, most of our patients were women, contrary to most previous studies on IDV/r in industrialized countries.
Previous studies demonstrated a higher IDV apparent bioavailability in females than in males or suggested a sex-related metabolism of IDV, but this is not likely to explain the lack of nephrological complications in our study [25, 26] .
One limitation of our study is the 6-month follow-up, compared with higher durations of exposure to IDV in previous studies in industrialized countries [3, 14, 16, 17] . However, the risk of IDV-associated renal complications has been reported to be higher in patients with IDV treatment < 74 weeks than in those with longer exposure [21] , and indinavir crystalluria is frequently observed soon after initiation of therapy [27] . Furthermore, our patients were followed up under cohort conditions, with no patients lost to follow up and with free access to a study clinic at any time. Under these circumstances, the frequency of urinary stones is not likely to have been greatly underestimated. Previous studies showed an increasing risk of urinary stones in Caucasian US patients [28] and a low incidence of IDV nephrological side effects in a population predominantly American with African ancestry [15] . Following these reports, our data support the hypothesis of a lower frequency of IDV-associated urinary stones in sub-Saharan African adults.
In our study, we were unable to assess the efficacy and tolerance of the IDV/r 400/100 mg dosage, because of the reduced number of patients who switched from the IDV/r 800/100 mg bid to the 400/100 mg bid dosage and of the consecutive reduced followed-up time on the 400/100 mg bid dosage. In industrialized countries, IDV/r is now given at the 400/100 mg bid dosage [29, 30] , provided that plasma concentration measurement-driven dosage adaptations are possible. In most sub-Saharan African areas, therapeutic drug monitoring is not routinely available. Given the low digestive tolerance -leading to low adherence -, and despite of the good nephrological tolerance of the 800/100 mg bid dosage in our study, 400/100 mg bid should probably be the recommended first-line dosage of IDV/r in sub-Saharan Africa.
However, this remains to be carefully evaluated in terms of efficacy and tolerance.
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* Patients with detectable ZDV plasma concentrations were suspected to have taken their antiretroviral drugs within the preceding eight hours. For these patients, the IDV plasma concentration was classified as non-C min (see figure 1A) * Patients with undetectable ZDV plasma concentrations were confirmed not to have taken their antiretroviral drugs within the preceding eight hours. For these patients, the IDV plasma concentration was classified as C min (see figure 1B) .
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